FDA Approves Augtyro for NTRK-Positive Advanced Solid Tumors

THURSDAY, June 20, 2024-- The U.S. Food and Drug Administration has approved Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor (TKI), for the treatment of patients with neurotrophic tyrosine receptor kinase (NTRK)-positive...